Antiemetic Guidelines: Not Just for the HEC of It

Restricted access

Disclosures: The author has disclosed that she has not received any financial consideration from any person or organization to support the preparation of this article.

Correspondence: Kelsey A. Klute, MD, 987680 Nebraska Medical Center, Omaha, NE 68198-7680. Email: Kelsey.klute@unmc.edu

View associated content

  • 1.

    Coates A, Abraham S, Kaye SB, . On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203208.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    ASCO. ASCO 50th Anniversary Poll Names the Top 5 Advances From the Past 50 Years. Accessed April 24, 2020. Available at: https://www.asco.org/about-asco/press-center/news-releases/asco-50th-anniversary-poll-names-top-5-advances-past-50-years

  • 3.

    Grunberg SM, Deuson RR, Mavros P, . Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:22612268.

  • 4.

    Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374:13561367.

  • 5.

    Navari RM, Qin R, Ruddy KJ, . Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134142.

  • 6.

    Ettinger DS, Berger MJ, Barbour S, . NCCN Clinical Practice Guidelines in Onocology: Antiemesis. Version 2.2020. Accessed May 8, 2020. To view the most recent version, visit NCCN.org.

  • 7.

    Hesketh PJ, Kris MG, Basch E, . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35:32403261.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hesketh PJ, Grunberg SM, Gralla RJ, . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the aprepitant protocol 052 study group. J Clin Oncol 2003;21:41124119.

    • Search Google Scholar
    • Export Citation
  • 9.

    Roeland EJ, Ruddy KJ, LeBlanc TW, . What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 2020;18:676681.

    • Search Google Scholar
    • Export Citation
  • 10.

    Schwartzberg LS, Grunberg SM, Kris MG. Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2011;9:114; quiz 15–6.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Clemons M, Bouganim N, Smith S, . Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2016;2:225231.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Ng T, Mazzarello S, Wang Z, . Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 2016;155:337344.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 2015;20:576583.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1095 1095 1069
PDF Downloads 230 230 223
EPUB Downloads 0 0 0